Investor Relations

Latest News

ASP Isotopes Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares

Read Press Release

ASP Isotopes Announces Pricing of Public Offering of Common Stock

Read Press Release

ASP Isotopes Announces Proposed Public Offering of Common Stock

Read Press Release

Latest Presentation

Company Presentation

Latest Event

Annual Meeting of Stockholders

Latest Financial Results

Q3 2024

Quarter Ended Sep 30, 2024

Latest Annual Filing

For Fiscal Year Ending December 31, 2023

Company Overview

ASP is an advanced materials company dedicated to developing technology and processes designed to produce and enrich isotopes used in multiple markets, which include Nuclear Medicine and therapeutics, green energy generation, and quantum computing.

Our initial focus is to utilize our proprietary ASP technology to construct, commission, and later produce commercial amounts of highly enriched isotopes for the Nuclear medicine market at our plants located in South Africa. We believe that the isotopes we may develop using the ASP technology have significant potential advantages to the end user, as well as commercial advantages due to companies’ Modular, cost-effective, and environmentally friendly processes.

We may also seek to use the ASP technology to separate other isotopes in the future, which we believe have potential applications in the quantum computing target end market and nuclear green energy end market.

We were incorporated in Delaware in September 2021. Our principal executive offices are located at 1101 Pennsylvania Avenue NW, Suite 300, Washington, DC 20004, and our website address is www.aspisotopes.com.

Stock Snapshot

IR Contacts

Headquarters

ASP Isotopes Inc.
1101 Pennsylvania Avenue NW
Suite 300
Washington DC 20004
United States

Investor Relations

Jason Assad
T: 561-709-3043
Jassad@aspisotopes.com

Transfer Agent

American Stock Transfer & Trust Company, LLC
6201 15th Ave
Brooklyn NY 11219
United States
T: 800-937-5449